TY - JOUR
T1 - Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment
T2 - A proton magnetic resonance spectroscopy and reliability study
AU - Plitman, Eric
AU - Chavez, Sofia
AU - Nakajima, Shinichiro
AU - Iwata, Yusuke
AU - Chung, Jun Ku
AU - Caravaggio, Fernando
AU - Kim, Julia
AU - Alshehri, Youssef
AU - Chakravarty, M. Mallar
AU - De Luca, Vincenzo
AU - Remington, Gary
AU - Gerretsen, Philip
AU - Graff-Guerrero, Ariel
N1 - Funding Information:
E.P. has received funding from the Vanier Canada Graduate Scholarship, the Ontario Graduate Scholarship, and the Canada Graduate Scholarship—Master's. P.G. has received fellowship awards from CIHR, the Ontario Mental Health Foundation (OMHF) and the Centre for Addiction and Mental Health (CAMH). S.N. has received fellowship grants from CIHR, research support from Japan Society for the Promotion of Science (16H06253), and manuscript fees or speaker's honoraria from Dainippon Sumitomo Pharma and Yoshitomi Yakuhin. Y.I. has received fellowship grants from CIHR, Keio University Medical Science Foundation, Mitsukoshi Foundation, Japan Foundation for Aging and Health, and manuscript fees from Dainippon Sumitomo Pharma. J.K.C. has received funding from the CIHR Doctoral Award and the Canada Graduate Scholarship—Master's. Y.A. has received conference travel support from Lundbeck and Janssen. G.R. has received consultant fees from Neurocrine Biosciences and Synchroneuron, as well as research support from CIHR, Research Hospital Fund–Canada Foundation for Innovation (RHF-CFI), and Novartis. A.G.-G. has received support from the United States National Institute of Health, CIHR, OMHF, Consejo Nacional de Ciencia y Tecnología, the Instituto de Ciencia y Tecnología del DF, the Brain & Behavior Research Foundation (Formerly NARSAD), the Ontario Ministry of Health and Long-Term Care, the Ontario Ministry of Research and Innovation Early Research Award, and Janssen. All other authors have declared that there are no conflicts of interest in relation to the subject of this study.
Funding Information:
This work was supported by the Canadian Institute of Health Research (CIHR) ( MOP-142493 and 141968 to A.G.-G.), Ontario Mental Health Foundation Type A grant (A.G.-G), Early Researcher Award, Ministry of Economic Development and Innovation (A.G.-G), Academic Health Science Centre Alternative Funding Plan of Ontario (A.G.-G), Vanier Canada Graduate Scholarship (E.P.), Ontario Graduate Scholarship (E.P.), and Canada Graduate Scholarship – Master's. These sources were not involved in study design, data collection, data analysis, data interpretation, manuscript writing, or the decision to submit the paper for publication. We would like to acknowledge the invaluable assistance provided by Dr. Nancy Lobaugh and Anusha Ravichandran, as well as the expertise and support provided by Dr. Jamie Near.
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/3/30
Y1 - 2018/3/30
N2 - Previous proton magnetic resonance spectroscopy ( 1 H-MRS) studies have reported disrupted levels of various neurometabolites in patients with schizophrenia. An area of particular interest within this patient population is the striatum, which is highly implicated in the pathophysiology of schizophrenia. The present study examined neurometabolite levels in the striatum of 12 patients with schizophrenia receiving antipsychotic treatment for at least 1 year and 11 healthy controls using 3-Tesla 1 H-MRS (PRESS, TE = 35 ms). Glutamate, glutamate+glutamine (Glx), myo-inositol, choline, N-acetylaspartate, and creatine levels were estimated using LCModel, and corrected for fraction of cerebrospinal fluid in the 1 H-MRS voxel. Striatal neurometabolite levels were compared between groups. Multiple study visits permitted a reliability assessment for neurometabolite levels (days between paired 1 H-MRS acquisitions: average = 90.33; range = 7–306). Striatal neurometabolite levels did not differ between groups. Within the whole sample, intraclass correlation coefficients for glutamate, Glx, myo-inositol, choline, and N-acetylaspartate were fair to excellent (0.576–0.847). The similarity in striatal neurometabolite levels between groups implies a marked difference from the antipsychotic-naïve first-episode state, especially in terms of glutamatergic neurometabolites, and might provide insight regarding illness progression and the influence of antipsychotic medication.
AB - Previous proton magnetic resonance spectroscopy ( 1 H-MRS) studies have reported disrupted levels of various neurometabolites in patients with schizophrenia. An area of particular interest within this patient population is the striatum, which is highly implicated in the pathophysiology of schizophrenia. The present study examined neurometabolite levels in the striatum of 12 patients with schizophrenia receiving antipsychotic treatment for at least 1 year and 11 healthy controls using 3-Tesla 1 H-MRS (PRESS, TE = 35 ms). Glutamate, glutamate+glutamine (Glx), myo-inositol, choline, N-acetylaspartate, and creatine levels were estimated using LCModel, and corrected for fraction of cerebrospinal fluid in the 1 H-MRS voxel. Striatal neurometabolite levels were compared between groups. Multiple study visits permitted a reliability assessment for neurometabolite levels (days between paired 1 H-MRS acquisitions: average = 90.33; range = 7–306). Striatal neurometabolite levels did not differ between groups. Within the whole sample, intraclass correlation coefficients for glutamate, Glx, myo-inositol, choline, and N-acetylaspartate were fair to excellent (0.576–0.847). The similarity in striatal neurometabolite levels between groups implies a marked difference from the antipsychotic-naïve first-episode state, especially in terms of glutamatergic neurometabolites, and might provide insight regarding illness progression and the influence of antipsychotic medication.
KW - Antipsychotics
KW - Glutamate
KW - Glx
KW - Striatum
UR - http://www.scopus.com/inward/record.url?scp=85042905959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042905959&partnerID=8YFLogxK
U2 - 10.1016/j.pscychresns.2018.01.004
DO - 10.1016/j.pscychresns.2018.01.004
M3 - Article
C2 - 29414127
AN - SCOPUS:85042905959
SN - 0925-4927
VL - 273
SP - 16
EP - 24
JO - Psychiatry Research - Neuroimaging
JF - Psychiatry Research - Neuroimaging
ER -
